Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT06021756Phase 1Unknown
- Sponsor
- University of Arizona
- Start
- Jul 2019
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of ketamine in levodopa-induced dyskinesia (LID), sponsored by University of Arizona. Primary endpoint: Unified Dyskinesia Rating Scale at 12 weeks. Status: unknown.
02
Drugs
ketamine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT06021756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021756.